Melanie Dowson
4 Papers
Melanie Dowson is an academic researcher. The author has contributed to research in topics: Prostate cancer & Rucaparib. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Martin Bambury,Eric Voog,Jingsong Zhang,Josep M. Piulats,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Celestia S. Higano,Laurence Eliot Miles Krieger,Cora N. Sternberg,Simon Paul Watkins,Darrin Despain,Andrew Simmons,Andrea Loehr,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury,Simon Chowdhury +27 more
TL;DR: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
605
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim Abida,David Campbell,Akash Patnaik,Jeremy Shapiro,Brieuc Sautois,Nicholas J. Vogelzang,Eric Voog,Alan H. Bryce,Ray McDermott,Francesco Ricci,Julie Rowe,Jingsong Zhang,Josep M. Piulats,Karim Fizazi,Axel S. Merseburger,Celestia S. Higano,Laurence Eliot Miles Krieger,Charles J. Ryan,Felix Y. Feng,Andrew Simmons,Andrea Loehr,Darrin Despain,Melanie Dowson,Foad Green,Simon Paul Watkins,Tony Golsorkhi,Simon Chowdhury +26 more
TL;DR: In this prospective, genomics-driven study of rucaparib in mCRPC, limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2 are found, however, patients with alteration in other DDR-associated genes (e.g., PALB2) may benefit from ParP inhibition.
345
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Wassim Abida,David Campbell,Akash Patnaik,Alan H. Bryce,Jeremy Shapiro,Richard Martin Bambury,Jingdong Zhang,John M. Burke,Daniel Castellano,Albert Font,Vinod Ganju,Anne-Claire Hardy-Bessard,Ray McDermott,Brieuc Sautois,Dominique Spaeth,Eric Voog,Josep M. Piulats,Elias Pintus,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Andrea Loehr,Darrin Despain,Andrew Simmons,Melanie Dowson,Jowell Go,Simon Paul Watkins,Simon Chowdhury +29 more
TL;DR: TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA or other DNA damage repair (DDR) gene alteration as discussed by the authors .
42
Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).
Wassim Abida,David Campbell,Akash Patnaik,Brieuc Sautois,Jeremy Shapiro,Nicholas J. Vogelzang,Alan H. Bryce,Raymond S. McDermott,Francesco Ricci,Julie Rowe,Jingsong Zhang,Andrea Loehr,Darrin Despain,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury +15 more
TL;DR: The phase 2 TRITON2 study is evaluating the PARP inhibitor rucaparib in pts with mCRPC and a deleterious germline or somatic alteration in BRCA (BRCA pts) or 1 of 13 ot...